.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Healthtrust
Julphar
Boehringer Ingelheim
US Army
Moodys
Express Scripts
Farmers Insurance
Novartis
UBS
Citi

Generated: September 20, 2017

DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

« Back to Dashboard

Claims for Patent: ► Subscribe

Title:Antitumoral use of cabazitaxel
Abstract: The invention relates to a compound of formula: ##STR00001## which may be in base form or in the form of a hydrate or a solvate, in combination with prednisone or prednisolone, for its use as a medicament in the treatment of prostate cancer, particularly metastatic prostate cancer, especially for patients who are not catered for by a taxane-based treatment.
Inventor(s): Gupta; Sunil (Chester Springs, PA)
Assignee: Aventis Pharma SA (Antony, FR)
Application Number:13/456,720
Patent Claims: 1. A method for treating a patient with prostate cancer that has progressed during or after treatment with docetaxel, comprising administering to said patient a dose of 20 to 25 mg/m.sup.2 of cabazitaxel, or a hydrate or solvate thereof, in combination with a corticoid.

2. The method according to claim 1, where the prostate cancer is an advanced metastatic disease.

3. The method according to claim 1, where the cabazitaxel is in the form of an acetone solvate.

4. The method according to claim 3, in which the acetone solvate contains between 5% and 8% by weight of acetone.

5. The method according to claim 1, comprising repeating the administration of cabazitaxel, or hydrate or solvate thereof, as a new cycle every 3 weeks.

6. The method according to claim 1, wherein the cabazitaxel is in base form.

7. The method according to claim 1, wherein said cabazitaxel, or hydrate or solvate thereof, is administered in an amount to provide an AUC of about 991 ngh/mL (CV 34%).

8. The method according to claim 1, wherein said cabazitaxel, or hydrate or solvate thereof, is administered in an amount to provide an C.sub.max of about 226 ngh/mL (CV 107%).

9. The method according to claim 1 wherein said cabazitaxel, or hydrate or solvate thereof, is administered in an amount to provide a plasma clearance of 48.5 L/h (CV 39%).

10. The method according to claim 1, further comprising monitoring blood counts and measuring neutrophil levels in the patient.

11. The method according to claim 10, further comprising discontinuing cabazitaxel treatment in a patient with a neutrophil count of .ltoreq.1,500 cells/mm.sup.3.

12. The method according to claim 1, where the cabazitaxel, or hydrate or solvate thereof, is administered at a dose of 25 mg/m.sup.2.

13. The method according to claim 1, wherein the corticoid is selected from the group consisting of prednisone and prednisolone.

14. The method according to claim 13, where the prednisone or prednisolone is administered at a dose of 10 mg/day.

15. The method according to claim 14, where the cabazitaxel, or hydrate or solvate thereof, is administered at a dose of 20 mg/m.sup.2.

16. The method according to claim 14, where the cabazitaxel, or hydrate or solvate thereof, is administered at a dose of 25 mg/m.sup.2.

17. The method according to claim 1, where the prostate cancer is a castration resistant or hormone-refractory prostate cancer.

18. The method according to claim 17, where the cabazitaxel, or hydrate or solvate thereof, is administered at a dose of 25 mg/m.sup.2.

19. The method according to claim 17, comprising repeating the administration of said cabazitaxel, or hydrate or solvate thereof, as a new cycle every 3 weeks.

20. The method according to claim 1, wherein the prostate cancer is a castration resistant or hormone-refractory, metastatic prostate cancer.

21. The method according to claim 20, where the cabazitaxel, or hydrate or solvate thereof, is administered at a dose of 20 mg/m.sup.2.

22. The method according to claim 20, where cabazitaxel, or hydrate or solvate thereof, is administered at a dose of 25 mg/m.sup.2.

23. The method according to claim 20, comprising repeating the administration of said cabazitaxel, or hydrate or solvate thereof, as a new cycle every 3 weeks.

24. The method according to claim 1, wherein the prostate cancer is a castration resistant or hormone-refractory, metastatic prostate cancer, and wherein the corticoid is selected from the group consisting of prednisone and prednisolone, and wherein the cabazitaxel, or hydrate or solvate thereof, is administered at a dose of 25 mg/m.sup.2.

25. The method according to claim 24, comprising repeating the administration of said cabazitaxel, or hydrate or solvate thereof, as a new cycle every 3 weeks.

26. The method according to claim 1, where the cabazitaxel, or hydrate or solvate thereof, is administered at a dose of 20 mg/m.sup.2.

27. A method of increasing the survival of a patient with a castration resistant or hormone refractory, metastatic prostate cancer that has progressed during or after treatment with docetaxel, comprising administering a dose of 20 to 25 mg/m.sup.2 of cabazitaxel, or hydrate or solvate thereof, to the patient in combination with prednisone or prednisolone.

28. The method according to claim 27, where the cabazitaxel, or hydrate or solvate thereof, is administered at a dose of 25 mg/m.sup.2.

29. The method according to claim 27, comprising repeating the administration of said cabazitaxel, or hydrate or solvate thereof, as a new cycle every 3 weeks.

30. The method according to claim 27, where the cabazitaxel, or hydrate or solvate thereof, is administered at a dose of 20 mg/m.sup.2.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

UBS
Boehringer Ingelheim
Fuji
Harvard Business School
Mallinckrodt
US Department of Justice
Deloitte
AstraZeneca
Moodys
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot